Loading stock data…
$16.82+0.10 (+0.60%)
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
Rallybio Corporation in the Healthcare sector is trading at $16.82 with a market capitalization of $89M. The stock is currently near its 52-week high of $17.57, remaining 36.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $212,000↓ | $222,000↑ | $212,000 | $212,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.65M↑ | -$8.73M↓ | -$6.41M↑ | -$6.92M↑ | -$10.06M |
| Net Income | $43.66M↑ | -$8.28M↓ | -$5.85M↓ | $16.02M↑ | -$9.70M |
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibito...